Cyclerion Therapeutics, Inc. (CYCN)
| Market Cap | n/a+34.1% |
| Revenue (ttm) | n/a |
| Net Income | n/a |
| EPS | n/a |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 435,847 |
| Open | n/a |
| Previous Close | 23.52 |
| Day's Range | 2.82 - 23.52 |
| 52-Week Range | 2.82 - 59.36 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
Insiders here have filed 4 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
$CYCN stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in CYCN holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by CYCN's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
CYCN Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New CYCN patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to CYCN from public contracts
Source: USAspending.gov
CYCN Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from CYCN’s recent data — informational, not investment advice